Clinical Evaluation, Biomarkers and Metabolomics of Sarcopenia in Frail Older Adults at Ambulatory Clinics
This trial is active, not recruiting.
|Sponsor||National Taiwan University Hospital|
|Collaborator||National Health Research Institutes, Taiwan|
|Start date||January 2011|
|End date||December 2018|
|Trial size||350 participants|
|Trial identifier||NCT02073370, 201010021R, EC0991002-E|
Sarcopenia related mobility dysfunction was a preventable presentation in transitional variation of frailty. However, the definition, associated risk factors, clinical course and outcome of sarcopenia in Taiwanese older adults are still under-clarified and need for further study.
The research subjects will be culled from outpatients aged over 65 at NTUH; 1000 Taiwanese subjects aged 20-40 equally divided in both genders will be recruited in order to establish the norm of Taiwanese's skeletal muscle index.
Domestic operation tool of sarcopenia for older adults
time frame: Baseline
Change from baseline in body composition during aging
time frame: up to 2 years
Male or female participants at least 65 years old.
- functional decline in recent one year
- cognitive impairment
- depressive symptom
- mobility impairment
- fall in recent one year
- eating or feeding problems
- weight loss
- co-morbid conditions≧5
- tracking by different physician ≧3 in recent half year
- poly-pharmacy≧8 in recent 3 months
- hospitalization ≧1 in recent one year
- emergency visits≧2 in recent one year
- aged ≧ 80.
- non-ambulatory (bed-ridden) patients
- long-term residents at nursing homes
- patients with a life expectancy shorter than six months
- impairment in vision, hearing, or communicative ability, making convenience of clinical evaluation during the study period impossible.
|Official title||Clinical Evaluation, Biomarkers and Metabolomics of Sarcopenia in Frail Older Adults at Ambulatory Clinics|
|Principal investigator||Ching-Yu Chen, MD|
Call for more information